Tags : PMBCL

Kite’s Yescarta Receives EU Marketing Approval

Shots: Post FDA approval in 2017, Yescarta (axicabtagene ciloleucel) receives EU marketing approval for the treatment of Relapsed or Refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) The approval is based on ZUMA-1 trial with (N=101) results: 72%( 73/101) responded to therapy; 51%(52/101) achieved complete response; with one-year infusion- 60% […]Read More